Apligraf

DEVICE6 trials

Sponsors

Organogenesis, University Hospital, Basel, Switzerland

Conditions

Epidermolysis BullosaEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa, JunctionalKeloidVaricose UlcerVenous Leg UlcersVenous UlcerWound Healing

Phase 1

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

CompletedNCT00587587

OrganogenesisKeloid

Start: 2007-12-31End: 2010-03-31Updated: 2011-08-19

Phase 3

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

TerminatedNCT00587223

OrganogenesisEpidermolysis Bullosa Dystrophica, Epidermolysis Bullosa, Junctional

Start: 2007-12-31End: 2008-12-31Updated: 2010-06-29

Phase 4

A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers

WithdrawnNCT00648674

OrganogenesisVaricose Ulcer

Start: 2008-07-31End: 2010-03-31Updated: 2015-08-19

A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

CompletedNCT01327937

OrganogenesisVenous Ulcer

Start: 2011-03-31End: 2013-12-31Updated: 2015-09-24

A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa

TerminatedNCT01619670

University Hospital, Basel, SwitzerlandEpidermolysis Bullosa, Wound Healing

Start: 2012-06-30End: 2015-01-31Updated: 2015-03-10

A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®

OrganogenesisVenous Leg Ulcers

Start: 2013-11-30End: 2014-01-31Target: 100Updated: 2013-12-13

Related Papers

A bioengineered living cell construct activates metallothionein/zinc/MMP8 and inhibits TGF<b>β</b> to stimulate remodeling of fibrotic venous leg ulcers

Wound Repair and Regeneration2019-11-0132 citations

A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers

Science Translational Medicine2017-01-04140 citations